Price movement over the last 24 hours
Global X Artificial Intelligence & Technology ETF vs Heron Therapeutics Inc — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $62.06, while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: Global X Artificial Intelligence & Technology ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AIQ | HRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $2.23 |
52-Week Low | $43.28 | $0.39 |
Market Cap | — | $80.58M |
Enterprise Value | — | $178.48M |
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.84, up 3.22% with a neutral technical signal. The ETF shows strong momentum with moving averages indicating bullish sentiment while oscillators remain neutral. Recent performance highlights include turning $10,000 into $13,400 over six months, outperforming broader market indices. The fund has gained attention for its AI-focused strategy amid expanding market interest beyond mega-cap technology stocks.
The outlook remains positive as AI adoption accelerates, though valuations require monitoring. Key risks include thematic ETF concentration and fee structure considerations. Institutional interest in AI infrastructure spending supports long-term growth potential, but market volatility around AI stock rotations presents near-term challenges.
HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.
Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.
Trailing returns across standard periods
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →